Handa's Generic Dexilant Infringes Takeda IP, Judge Hears

Law360, San Francisco (June 5, 2013, 4:29 PM EDT) -- Handa Pharmaceuticals should be blocked from making a generic version of the acid-reflux drug Dexilant because the drug cannot be produced without infringing Takeda Pharmaceutical Co.'s patented manufacturing process, Takeda argued Wednesday at the opening of a bench trial on Takeda's patent claims.

Takeda's scientists developed a unique way of producing the crystalline version of dexlansoprazole used in its delayed-release Dexilant capsules, and refractogram images of Handa's generic version show similar crystal structures that could only be produced by copying Takeda's patented methods, Jeffrey Weinberger with Munger...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.